Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Developments and Pipeline Progress
TERN logo

Terns Pharmaceuticals Pivots to Oncology with 75% Response Rate in Leukemia Trial and Cash Runway into 2028

TERN10-QFiling Date: 11/10/2025
Terns Pharmaceuticals, Inc.
Description

What this story covers

Terns Pharmaceuticals has strategically shifted focus to its lead oncology candidate, TERN-701, following promising Phase 1 data. Despite a $72.6 million net loss, the company maintains a robust $295.6 million cash reserve, funding operations through 2028.

Story snapshot

CompanyTerns Pharmaceuticals, Inc.
TickerTERN
VariantStandard detailed
Duration11:39
Filing type10-Q
PeriodQ3 2025
IndustryHealthcare & Pharmaceuticals
Accession0001193125-25-274367
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-QView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in